Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
2665529
Reference Type
Journal Article
Title
Pimecrolimus 1% cream for oral erosive lichen planus: a 6-week randomized, double-blind, vehicle-controlled study with a 6-week open-label extension to assess efficacy and safety
Author(s)
Mccaughey, C; Machan, M; Bennett, R; Zone, JJ; Hull, CM
Year
2011
Is Peer Reviewed?
Yes
Journal
Journal of the European Academy of Dermatology and Venereology
ISSN:
0926-9959
EISSN:
1468-3083
Volume
25
Issue
9
Page Numbers
1061-1067
PMID
21175873
DOI
10.1111/j.1468-3083.2010.03923.x
Web of Science Id
WOS:000293556400010
Abstract
Objective To assess the efficacy and safety of topical pimecrolimus 1% cream in the treatment of oral erosive lichen planus.
Design A 6-week randomized, double-blind, vehicle-controlled phase followed by a 6-week open-label phase.
Setting Outpatients of the Department of Dermatology, University of Utah.
Patients Twenty-one patients with oral erosive lichen planus were randomized and treated with either pimecrolimus 1% cream or vehicle cream.
Intervention Pimecrolimus 1% cream, or its vehicle, were applied twice daily for 6 weeks to each side of the mouth with a 2 x 2 inch gauze pad folded in half and placed directly on the erosive lesion.
Main Outcome Measures Efficacy was based on clinical evaluation of Investigator's Global Assessment (IGA) of the overall severity of the disease, erythema, measurement of the size of any target erosion in millimetres, and assessment of spontaneous pain. Blood levels of pimecrolimus were monitored in all subjects on day 0 and repeated on day 7.
Results Pimecrolimus 1% cream was superior to vehicle cream in reducing mean IGA, pain, and erosion size. For the vehicle group that entered the open-label phase, pimecrolimus 1% cream improved the mean IGA, pain, erosion size, and erythema. Pimecrolimus levels were detected in nine out of 10 of the pimecrolimus-treated subjects. These levels were consistently low. The pimecrolimus cream was well-tolerated. No clinically relevant, drug-related adverse events were reported.
Conclusion Pimecrolimus 1% cream was superior to vehicle in reducing pain, erythema, decreasing erosion size, and improving overall severity of disease when compared with vehicle treatment.
Keywords
elidel cream; oral lichen planus; pimecrolimus cream
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity